59844-05-2

Usage

Uses

Used in Organic Synthesis:
3-(2-Nitrophenyl)-1H-pyrazole is used as a building block in organic synthesis for its ability to contribute to the formation of complex molecular structures. Its presence in the synthesis process can enhance the reactivity and selectivity of the resulting compounds.
Used in Chemical Reactions:
As a reagent, 3-(2-Nitrophenyl)-1H-pyrazole is utilized in various chemical reactions to facilitate specific transformations, such as the formation of new bonds or the alteration of existing ones, due to the reactivity of the nitro group.
Used in Pharmaceutical Industry:
3-(2-Nitrophenyl)-1H-pyrazole is used as a precursor in the synthesis of pharmaceutical drugs, where its unique properties can contribute to the development of new therapeutic agents with improved efficacy and selectivity.
Used in Agrochemicals:
In the agrochemical industry, 3-(2-Nitrophenyl)-1H-pyrazole serves as a precursor in the synthesis of agrochemicals, potentially leading to the creation of novel pesticides or herbicides with enhanced performance.
Used in Biochemical Studies:
3-(2-Nitrophenyl)-1H-pyrazole is employed as a probe in biochemical research, where its chemical properties can be exploited to investigate biological processes or to interact with biological targets, providing insights into molecular mechanisms.

Upstream product

• 577-59-3 2-acetylnitrobenzene 
• 87488-61-7 3-(dimethylamino)-1-(2-nitrophenyl)prop-2-en-1-one 
• 1072-63-5 1-vinylimidazole 
• 153813-81-1 (E)-3-(N,N-dimethylamino)-1-(2-nitrophenyl)-2-propen-1-one 

Downstream Products

• 305811-47-6 1-methyl-3-(2-nitrophenyl)pyrazole 
• 87488-80-0 2-(1-methyl-1H-pyrazol-3-yl)-phenylamine 
• 111562-32-4 2-(1H-pyrazol-3-yl)aniline 
• 111562-32-4 5-(2-aminophenyl)-1H-pyrazole 
• 59844-06-3 N,N,α-trimethyl-3-(o-nitrophenyl)pyrazole-1-acetamide 

Relevant academic research and scientific papers

Discovery of novel 2,4-diarylaminopyrimidine derivatives as potent and selective epidermal growth factor receptor (EGFR) inhibitors against L858R/T790M resistance mutation

A series of novel 2,4-diarylaminopyrimidine derivatives of AZD9291 were discovered as L858R/T790M mutant selective epidermal growth factor receptor (EGFR) inhibitors. The majority of these compounds exhibited moderate to excellent EGFR T790 M/L858R inhibitory activities and comparable anti-proliferative activities against double mutant over-expressed NCI-H1975 cells to that of AZD9291. The most promising compounds 8a displayed an IC50 of 4.1 nM against EGFR L858R/T790M mutants. 8a also showed excellent cytotoxic effect against NCI-H1975 cells with an IC50 of 59 nM and 100-fold selectivity over wide-type EGFR over-expressed A431 cells. Compound 8a significantly inhibited tumor growth in NCI-H1975 xenograft models at a non-toxic dose. Docking study performed for 8a with ATP binding site of EGFR-TK showed the similar binding mode to that of AZD9291. All these results suggested that compound 8a was a potential mutant-selective EGFR inhibitor.

Pyrimidine compounds

The present invention belongs to the field of pharmaceutical synthesis, and relates to pyrimidine compounds, a preparation method and applications thereof, a pharmaceutical composition containing the pyrimidine compounds as active components, and applications of the pyrimidine compounds in preparation of antitumor drugs. The present invention discloses a pyrimidine compound having a structure represented by a formula I, wherein W is NH, R1 is a nitrogen-containing five-membered heterocyclic ring, and R2 is a nitrogen-containing basic group. According to the present invention, the pyrimidine compound can inhibit a variety of tumor cells, can particularly and selectively act on EGFRL858R/T790M lung cancer cells, and can overcome the existing EGFR inhibitors, wherein the IC50 of the compounds is increased by 10-100 times compared to wild-type cells. The formula I is defined in the specification.

TRIAZOLO- AND PYRAZOLOQUINAZOLINE DERIVATIVES AS PDE10A ENZYME INHIBITOR

The invention relates to compounds of the formula (I) and their use as pharmaceutical ingredients, in particular for the treatment of CNS related diseases.

A simple synthesis of 5-(2-Aminophenyl)-1H-pyrazoles

A four-step synthesis of 1-substituted 5-(2-aminophenyl)-1H-pyrazoles 5 as a novel type of histamine analogs and versatile building blocks for further transformations was developed. The synthesis starts from commercially available 2-nitroacetophenone (12), which is converted into the enamino ketone 13 as the key intermediate. Cyclization of the key intermediate 13 with monosubstituted hydrazines 14a-14l afforded the 5-(2-nitrophenyl)-1H-pyrazoles 17a-17l. Finally, catalytic hydrogenation of the nitro compounds 17a, 17c-17e, and 17g-17j furnished the title compounds 5a, 5c-5e, and 5g-5j, respectively, in good yields. As demonstrated by some further transformations, additional functionalization of compounds 17 and 5 is feasible, either by electrophilic substitution at C(4) of the pyrazole ring, or at the NH2 group. Copyright

Easily attachable and detachable ortho-directing agent for arylboronic acids in ruthenium-catalyzed aromatic C-H silylation

(Chemical Equation Presented) o-C?H silylation of arylboronic acids has been achieved using 2-pyrazol-5-ylaniline as an orthodirecting agent, which was temporarily attached to the boronyl group via Ru-catalyzed silylation with hydrosilanes. Condensation products of arylboronic acids with2-pyrazol-5-ylaniline were prepared in situ and subjected to reaction w ith triorganosilanes in the presence of RuH2(CO)(PPh3) 3 at 135°C. Regioselective silylation at their ortho-positions proceeded in good yields for phenylboronic acids bearing para-substituents such as chloro, fluoro, methyl, methoxy, and trifluoromethyl groups. p-Methoxycarbonyl-substituted phenylboronic acid provided thecorresponding silylated product in moderate yield. m-Tolyl- and 2-napht hylboronic acids underwent silylation selectively at the less stericallyhindered ortho-positions. The silylated products were utilized in Suzuk i?Miyaura coupling, followed either by iodination with ICl or by Tamao oxidation to furnish iodine- or hydroxy-substituted biaryls.

Pyrazole compounds

Aryl substituted pyrazole derivatives are provided, as well as processes for their preparation. The invention also provides compositions and methods for the treatment of HCV by administering a compound of the present invention, alone or in combination wit

Imidazoline derivatives as alpha-1A adrenoceptor ligands

Compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof are disclosed. Such compounds are useful in the treatment of Alpha-1A mediated diseases or conditions such as urinary incontinence.

2-(Anilinomethyl)imidazolines as α1 adrenergic receptor agonists: α1a subtype selective 2′-heteroaryl compounds

The structure-activity relationship of 2′-pyrrole, pyrazole and triazole substituted 2-(anilinomethyl)imidazolines as α1 adrenergic agonists was investigated. The size and orientation of substituents, as well as the position of the heteroatoms, were found to have a profound effect on the potency and selectivity of the molecules. Potent α1A subtype selective agonists have been identified.